Esperion Therapeutics Inc. (Nasdaq: ESPR), a commercial-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients with elevated LDL cholesterol, has announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at $2.50 per share. The company expects to raise approximately $75 million in gross proceeds, before deducting underwriting discounts, commissions, and other offering expenses. Esperion has also granted underwriters a 30-day option to purchase up to an additional 4,500,000 shares. Piper Sandler & Co. and Cantor Fitzgerald & Co. are serving as joint book-running managers for the offering, with Citizens JMP Securities, H.C. Wainwright & Co., and Needham & Company acting as co-managers. All shares in the offering will be sold by Esperion. The transaction is expected to close subject to customary closing conditions.